All In MedTech

Device Trial Radar · NCT00526487

Clinical Study to Assess Safety and Effectiveness of the Zenith® Dissection Endovascular System in Patients With Aortic Dissection

Evaluation of the Safety and Effectiveness Performance of the Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissection Involving the Descending Thoracic Aorta

Last checked: Nov 20, 2026Latest source record: Mar 1, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Dec 2007

Primary completion

Jul 2011

Study completion Sep 2016

Sponsor

Lead sponsor
William Cook EuropeNot on our public-company list
Sponsor type
Industry
Collaborators
Cook Group Incorporated; MED Institute, Incorporated; William Cook Australia
First posted
Sep 10, 2007

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Device feasibility
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness performance of the Zenith® Dissection Endovascular System in the treatment of aortic dissections involving the descending thoracic aorta.

Conditions

  • Aortic Dissection Involving the Descending Thoracic Aorta

Interventions

  • Zenith® Dissection Endovascular SystemDevice

    The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.

  • Endovascular RepairDevice

    Endovascular Repair

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary endpoint is survival at 30 daysTime frame: 30 days

Locations

8 sites in 5 countries. Site status is shown where the registry gives one.

  • St. Vincent's Hospital Melbourne

    Melbourne, Australia

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.